In parallel, another study using breast and lung cancer PDOs stratified by TP53 status demonstrated that combined treatment with talazoparib and temozolomide produced synergistic cytotoxicity exclusively in mutant p53 models. The gene discussed is TP53; the disease is lung cancer.